Tenax Therapeutics, Inc. (TENX) stock
TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.43+0.01 (+0.70%)
Close on Nov 18, 2026Market cap $53.52MP/E –Yield –
Tenax Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tenax Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$68.61M. For fiscal 2025 it was -$56.39M. The highest annual figure on record is $11.05M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$56.39M | – |
| FY2024 | Dec 31, 2024 | -$19.49M | – |
| FY2023 | Dec 31, 2023 | -$8.23M | -174.5% |
| FY2022 | Dec 31, 2022 | $11.05M | – |
| FY2021 | Dec 31, 2021 | -$32.73M | -431.7% |
| FY2020 | Dec 31, 2020 | $9.87M | – |
| FY2019 | Dec 31, 2019 | -$8.56M | – |
| FY2018 | Dec 31, 2018 | -$6.89M | – |
| FY2017 | Dec 31, 2017 | -$9.21M | – |
| FY2015 | Apr 30, 2015 | -$14.82M | – |
| FY2014 | Apr 30, 2014 | -$16.61M | – |
| FY2013 | Apr 30, 2013 | -$5.19M | – |
| FY2012 | Apr 30, 2012 | -$8.22M | -177.8% |
| FY2011 | Apr 30, 2011 | $10.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$18.78M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$16.57M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$16.45M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$16.81M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$11.79M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$11.34M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$7.30M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$4.62M | -318.1% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$3.67M | -397.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$3.91M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$13.13M | -613.9% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $2.12M | -27.4% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $1.24M | -56.8% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$1.54M | -156.6% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $2.55M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $2.92M | -23.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $2.86M | +45.7% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $2.72M | -88.6% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$62.24M | -2296.9% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $3.80M | +70.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $1.96M | -8.4% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $23.75M | +791.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $2.83M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $2.23M | -1.6% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $2.14M | +17.8% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $2.67M | +60.4% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$14.30M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $2.26M | +45.4% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $1.82M | -3.7% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $1.66M | +35.9% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$11.56M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $1.55M | +18.6% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $1.89M | -37.3% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $1.22M | -65.0% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$17.03M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $1.31M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $3.01M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $3.50M | – |
| Q4 FY2015CQ1 2015 | Apr 30, 2015 | -$5.12M | – |
| Q3 FY2015CQ4 2014 | Jan 31, 2015 | -$3.13M | – |
See a number that looks wrong?